NAVLIN Daily NewsCheckout Today’s News
Join us at EVERSANA’s inaugural Pharma Pricing & Contracting Innovation Conference (PCIC), which will take place March 3-4 at the Hyatt Place St. PetersburgInteract with a cohort of peers and industry executives where you will be inspired and educated as you discover new solutions and case studies, network with your peers, and experience the latest products and innovations aimed at improving decision making for pricing & market access professionalsConference registration includes access to workshops and conference content; complimentary breakfast, lunch, and snacks; an exclusive networking dinner; and copies of all presentations following the event
We are pleased to announce that NAVLIN Daily is an official media partner with the World Evidence, Pricing, and Access (EPA) Congress, taking place March 5 to 6, 2025, at the RAI Congress Centre in AmsterdamThe congress promises valuable insights from industry experts, including value-based pricing, real-world evidence, digital health, patient engagement, and biosimilarsNAVLIN Daily's dedicated team will be on-site and reporting on the event, bringing you invaluable insights from speakers and experts. As a valued NAVLIN customer, you can use our NAVLIN50 registration discount code for a 50% discount
The Haute Autorité de Santé (HAS) in France has released its Strategic Project 2025-2030, succeeding the previous 2019-2024 strategyThe plan outlines HAS aims to enhance economic assessments to better inform public decision-making, address rising healthcare costs, and collaborate with stakeholders and research institutionsWith the implementation of EU HTA Regulation 2021/2282, HAS seeks to strengthen its European presence, influence health policy, and actively contribute to shaping healthcare standards
France is cutting the price of Novo Nordisk's Victoza from EUR 87.49 to EUR 60.26 per box of two pre-filled pens, from February 15 onwardThe price cut comes as French authorities make moves to enforce stricter reimbursement conditions for GLP-1 receptor agonistsA generic version of Victoza was recently registered in France, adding potential competition in the GLP-1 market. However, there are currently no registered generics for Ozempic (semaglutide) or Trulicity (dulaglutide)
The Organisation of Pharmaceutical Producers of India (OPPI) has hailed the Union Budget 2025's patient-centric approach, particularly the expansion of cancer care facilities to enhance accessibility to cancer care, import duty exemptions on 36 essential medicines, the inclusion of 13 patient assistance programs (PAPs), and efforts to strengthen India’s healthcare workforceSpeaking to NAVLIN Daily, OPPI Director General Anil Matai commended these developments and emphasized the need for ongoing cooperation between the government and the pharmaceutical industryOPPI told NAVLIN DAILY that ahead of the budget, it had emphasized the need for policy-level clarifications, particularly regarding the expansion of import duty exemptions for lifesaving and oncology medications to reduce treatment costs
The European Commission has launched the first request submission period for joint scientific consultations (JSCs) under the HTA Regulation (EU) 2021/2282, running from February 3 to March 3, 2025Health technology developers (HTDs) can apply for JSCs for medicinal products, with consultation slots starting in June, July, and September 2025Products must be in the early planning stage and expected to undergo a Joint Clinical Assessment (JCA), with selection based on factors like unmet medical need and innovation potential
The new UK-wide Innovative Licensing and Access Pathway (ILAP) was launched on 30th January. It will open to new applications in March 2025 The National Health Insurance Service (NHIS) of Korea has launched this year’s purchase amount monitoring efforts to inform price limit revisions for certain drugs China’s centralized procurement system has expanded across borders for the first time. On January 9, the procurement platform extended operations to Fangchenggang, a coastal municipality within the autonomous region of Guangxi Zhuang
The new UK-wide Innovative Licensing and Access Pathway (ILAP) launches today, 30 January. It will open to new applications in March 2025Based on stakeholder feedback, the old ILAP system was seen as too lenient and unclear on entry criteria, with not enough input from the NHS. As a result, it is being overhauled with new entry criteria and more collaboration with the NHS - the revamped ILAP will offer a more "bespoke" service, according to the MHRA, with selective entry and increased dialogue between ILAP partner organizations and developers. It will also introduce a simpler roadmap and timelinesCEO of NICE, Samantha Roberts, shared her thoughts on the revised pathway: "The launch of this revised offer marks a significant milestone for the ILAP. As an organisation committed to getting the best care to people fast, we welcome any initiative that helps developers get transformative medicines into the NHS. The collaboration between partner organisations, industry and patients has really helped shape this new offer, and so we look forward to continuing this close working and delivering the ambitions of the ILAP."
Lyfegen and EVERSANA are teaming up to use AI-driven insights for drug pricing and accessThe collaboration connects NAVLIN by EVERSANA® with Lyfegen's Public Drug Agreement LibraryTogether, the two companies want to “harness cutting-edge AI to empower market access and pricing professionals with actionable insights,” adding “The joint agreement marks a key step in tackling rising drug costs and improving patient access globally.”
The U.S. Centers for Medicare & Medicaid Services (CMS) published its list of prescription drugs selected for the next round of Medicare Drug Price Negotiation, with Novo Nordisk’s blockbuster weight loss and diabetes products, Wegovy (semaglutide) and Ozempic (semaglutide), topping the list In his first week in office, President Donald Trump has asked federal health agencies to pause all external communications, issued an executive order to initiate the process of withdrawing the U.S. from the World Health Organization (WHO), and rescinded former President Biden's executive order 14087, Lowering Prescription Drug Costs for Americans The Beneluxa Initiative has identified 13 high-impact medicines for joint HTA submissions from over 200 candidates, based on criteria like new chemical entities and clinical game-changing potential
650+
+99%
<24
4,000+
24x7
99.5%
